BJC Reports (Aug 2024)

Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer

  • Gavin Frame,
  • Hon Leong,
  • Roni Haas,
  • Xiaoyong Huang,
  • Jessica Wright,
  • Urban Emmenegger,
  • Michelle Downes,
  • Paul C. Boutros,
  • Thomas Kislinger,
  • Stanley K. Liu

DOI
https://doi.org/10.1038/s44276-024-00085-3
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Metastatic relapse of prostate cancer after radiotherapy is a significant cause of prostate cancer-related morbidity and mortality. PLOD2 is a mediator of invasion and metastasis that we identified as being upregulated in our highly aggressive radiorecurrent prostate cancer cell line. Methods Patient dataset analysis was conducted using a variety of prostate cancer cohorts. Prostate cancer cell lines were treated with siRNA, or the drug PX-478 prior to in vitro invasion, migration, or in vivo chick embryo (CAM) extravasation assay. Protein levels were detected by western blot. For RNA analysis, RNA sequencing was conducted on PLOD2 knockdown cells and validated by qRT-PCR. Results PLOD2 is a negative prognostic factor associated with biochemical relapse, driving invasion, migration, and extravasation in radiorecurrent prostate cancer. Mechanistically, HIF1α upregulation drives PLOD2 expression in our radiorecurrent prostate cancer cells, which is effectively inhibited by HIF1α inhibitor PX-478 to reduce invasion, migration, and extravasation. Finally, the long non-coding RNA LNCSRLR acts as a promoter of invasion downstream of PLOD2. Conclusions Together, our results demonstrate for the first time the role of PLOD2 in radiorecurrent prostate cancer invasiveness, and point towards its potential as a therapeutic target to reduce metastasis and improve survival outcomes in prostate cancer patients.